Ethosuximide pharmacokinetics in a pregnant patient and her newborn.
Ethosuximide concentration in serum was monitored during the last trimester of pregnancy in a patient. After delivery, the decline in serum concentration of ethosuximide was observed in the nonnursing neonate. The half-life of elimination of transplacentally acquired ethosuximide in this neonate was 41.3 hr. The ratio of breast milk to maternal serum concentration of ethosuximide was approximately 1. A total daily exposure to ethosuximide of 12.8 to 38.4 mg (3.6 to 11.0 mg/kg) as a result of nursing was predicted.
D000328:Adult; D004305:Dose-Response Relationship, Drug; D004832:Epilepsy, Absence / Q000097:blood / Q000188:drug therapy*; D004830:Epilepsy, Tonic-Clonic / Q000097:blood / Q000188:drug therapy*; D005013:Ethosuximide / Q000097:blood / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange / Q000187:drug effects; D008895:Milk, Human / Q000378:metabolism; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy*
D005013:Ethosuximide